INM

InMed Pharmaceuticals Inc.

$15.56

19.65%

InMed Pharmaceuticals Inc. operates as a pharmaceutical drug development company in the United States. The company researches and develops cannabinoid-based pharmaceuticals products. Its product candidates include INM-901 for Alzheimer's disease, INM-089 for dry age-related macular degeneration, and INM-755, a cannabinol cream. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is based in Vancouver, Canada.

Source: Yahoo Finance
AI summary

Price & performance

1M+17.6%
3M-4.2%
YTD+42.8%
1Y-20.0%
52-week range—
Beta0.80
Full chart and returns against a benchmark

Q-Score

—/ 100

Quality against peers; 50 is the peer median.

Growth26
Risk33
Performance40
Valuation10
Profitability—
Leverage—
Sentiment—
Every score and metric

News sentiment

Open News

Latest results · FY 2026

Revenue—
Net income-$12.6M
Net margin—
Historical fundamentals

Red flags in filings

3active red flags
Going-concern doubtSep 9, 2026
Auditor changeJun 13, 2025
Exchange listing noticeSep 18, 2026
Filings, findings and the timeline

Revenue exposure

Largest customer26%
Regions, segments, customers and suppliers

Valuation

INMIndustryP/E—35.25P/S—2.74EV/EBITDA—16.35P/B—2.46PEG—0.87
Dividend yield0.00%
Every valuation metric

Earnings

Nov 5next report
EPS estimate—
Beats (last 4 quarters)—
Average surprise—
EPS revisions (30d)—
Every quarter against its estimate